Secondary outcome measures include the following: (1) The rate of change from baseline which is performed in the pre-observation period or reference day [Peak VO2, left ventricular EF in the echocardiogram, total points of the Hospital Anxiety and Depression Scale (HADS), muscle strength (grip strength and lower-limb extension power), absolute values of interleukin-6 (IL-6), and tumor necrosis factor (TNF)-α], Time taken for 50% subjects to achieve a 15% improvement in AT workload, which is defined as an event. The gene discussed is IL6; the disease is depressive symptom measurement.